Michel Obeid

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


47 publications

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2013 | 2009 | 2008 | 2007 | 2005 | 1994 | 1993 | 1989 |
2024
Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
Vicino A., Hottinger A.F., Latifyan S., Boughdad S., Becce F., Prior J.O., Kuntzer T., Brouland J.P., Dunet V., Obeid M. et al., 2024/04. Journal of neurology, 271 (4) pp. 1947-1958. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_29F8761FAE12]
2023
Novel targets for immune-checkpoint inhibition in cancer.
Borgeaud M., Sandoval J., Obeid M., Banna G., Michielin O., Addeo A., Friedlaender A., 2023/11. Cancer treatment reviews, 120 p. 102614. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FED5F30A54BE]
 
Neoadjuvant Immunotherapy: A Promising New Standard of Care.
Boydell E., Sandoval J.L., Michielin O., Obeid M., Addeo A., Friedlaender A., 2023/07/24. International journal of molecular sciences, 24 (14) p. 11849. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EBC57E22479F]
 
Cytokine storm complicated by cardiogenic shock induced by anti-HER2 therapies.
Godinho R., Noto A., Fenwick C., Stravodimou A., Hugelshofer S., Peters S., Hullin R., Obeid M., 2023/06. Journal for immunotherapy of cancer, 11 (6). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D3B4F544BDF7]
Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer.
Liu C., Shatila M., Mathew A., Machado A.P., Thomas A., Zhang H.C., Thomas A.S., Faleck D., Funchain P., Philpott J. et al., 2023/06. Journal of Cancer, 14 (10) pp. 1913-1919. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7A07F987C9FE]
A CD64/FcγRI-mediated mechanism hijacks PD-1 from PD-L1/2 interaction and enhances anti-PD-1 functional recovery of exhausted T cells.
Joo V., Petrovas C., de Leval L., Noto A., Obeid M., Fenwick C., Pantaleo G., 2023. Frontiers in immunology, 14 p. 1213375. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_431B1ABF3E8A]
Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial.
Stalder G., Suffiotti M., Segot A., Noto A., Pantaleo G., Spertini O., Obeid M., 2023/01/01. Haematologica, 108 (1) pp. 234-239. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5551F9C73188]
2022
A differential process mining analysis of COVID-19 management for cancer patients.
Cuendet M.A., Gatta R., Wicky A., Gerard C.L., Dalla-Vale M., Tavazzi E., Michielin G., Delyon J., Ferahta N., Cesbron J. et al., 2022/12/07. Frontiers in oncology, 12 p. 1043675. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_98AD494947E5]
 
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Haanen J., Obeid M., Spain L., Carbonnel F., Wang Y., Robert C., Lyon A.R., Wick W., Kostine M., Peters S. et al., 2022/12. Annals of oncology, 33 (12) pp. 1217-1238. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F3804F73BCD6]
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events.
Coukos A., Vionnet J., Obeid M., Bouchaab H., Peters S., Latifyan S., Wicky A., Michielin O., Chtioui H., Moradpour D. et al., 2022/10. Journal for immunotherapy of cancer, 10 (10) pp. e005635. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F836C2B098EA]
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
Obeid M., Suffiotti M., Pellaton C., Bouchaab H., Cairoli A., Salvadé V., Stevenel C., Hottinger R., Pythoud C., Coutechier L. et al., 2022/05/01. JAMA oncology, 8 (5) pp. e220446. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8956034C5615]
2021
 
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
Zou F., Faleck D., Thomas A., Harris J., Satish D., Wang X., Charabaty A., Ernstoff M.S., Glitza Oliva I.C., Hanauer S. et al., 2021/11. Journal for immunotherapy of cancer, 9 (11) pp. e003277. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D947D0B8BF9D]
68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis.
Boughdad S., Latifyan S., Fenwick C., Bouchaab H., Suffiotti M., Moslehi J.J., Salem J.E., Schaefer N., Nicod-Lalonde M., Costes J. et al., 2021/10. Journal for immunotherapy of cancer, 9 (10) pp. e003594. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6D88B7F593BA]
 
Reactivation of IgA vasculitis after COVID-19 vaccination.
Obeid M., Fenwick C., Pantaleo G., 2021/09. The Lancet. Rheumatology, 3 (9) pp. e617. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1D8F6DD0B85B]
 
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E., Wicky A., Bouchaab H., Imbimbo M., Delyon J., Gautron Moura B., Gérard C.L., Latifyan S., Özdemir B.C., Caikovski M. et al., 2021/05. European journal of cancer, 149 pp. 153-164. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4791AD7F437D]
Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.
Moi L., Bouchaab H., Mederos N., Nguyen-Ngoc T., Perreau M., Fenwick C., Vaucher J., Sempoux C., Peters S., Obeid M., 2021/02. Journal of thoracic oncology, 16 (2) pp. 318-326. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3FFE3BA356BB]
2020
 
Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis.
Özdemir B.C., Latifyan S., Perreau M., Fenwick C., Alberio L., Waeber G., Spertini F., de Leval L., Michielin O., Obeid M., 2020/12. Annals of oncology, 31 (12) pp. 1775-1778. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DC85C792AD0C]
 
Effets indésirables immunomédiés des inhibiteurs de points de contrôle immunitaire: point de vue de l’interniste [Immune-related adverse events of checkpoint inhibitors: an internist/general practitioner's point of view]
Cisarovsky C., Kraege V., Obeid M., Garnier A., 2020/11/25. Revue medicale suisse, 16 (716) pp. 2264-2270. Peer-reviewed.
[DOI][Pmid][serval:BIB_DE32CC592446]
Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis.
Doms J., Prior J.O., Peters S., Obeid M., 2020/09. Annals of oncology, 31 (9) pp. 1273-1275. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_36FA44B46F63]
 
Personalized treatment of immune-related adverse events - balance is required.
Martins F., Obeid M., 2020/08. Nature reviews. Clinical oncology, 17 (8) p. 517. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_483DF1AA5D60]
Cardiotoxicité des inhibiteurs de points de contrôle immunitaire utilisés dans le traitement des cancers [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment]
Arangalage D., Pavon A.G., Hugelshofer S., Desgraz B., Tzimas G., Delyon J., Muller O., Obeid M., Ribi C., Michielin O. et al., 2020/06/03. Revue medicale suisse, 16 (696) pp. 1165-1168. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A124D4D50BD9]
 
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy.
Haanen J., Ernstoff M.S., Wang Y., Menzies A.M., Puzanov I., Grivas P., Larkin J., Peters S., Thompson J.A., Obeid M., 2020/06. Annals of oncology, 31 (6) pp. 724-744. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4BA2439C7A4C]
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.
Haanen J., Ernstoff M., Wang Y., Menzies A., Puzanov I., Grivas P., Larkin J., Peters S., Thompson J., Obeid M., 2020/06. Journal for immunotherapy of cancer, 8 (1) pp. e000604. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D60E64350838]
COVID-19 and lung cancer: risks, mechanisms and treatment interactions.
Addeo A., Obeid M., Friedlaender A., 2020/05. Journal for immunotherapy of cancer, 8 (1) pp. e000892. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_03895CF65905]
 
A Diffuse Medullary Hypercaptation With No Bone Lesion.
Christin A., de Leval L., Obeid M., 2020/02/01. JAMA oncology, 6 (2) pp. 291-292. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CCEF961A6931]
2019
 
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F., Sofiya L., Sykiotis G.P., Lamine F., Maillard M., Fraga M., Shabafrouz K., Ribi C., Cairoli A., Guex-Crosier Y. et al., 2019/09. Nature reviews. Clinical oncology, 16 (9) pp. 563-580. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7F8DDEE8DA1E]
 
Allergologie-immunologie: Effets secondaires des immunothérapies du cancer : du travail pour l’immunologue clinique [Side effects of cancer immunotherapies : important role for the clinical immunologist]
Obeid M., 2019/01/09. Revue medicale suisse, 15 (N° 632-633) pp. 17-19. Peer-reviewed.
[Pmid][serval:BIB_C148880B688D]
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
Martins F., Sykiotis G.P., Maillard M., Fraga M., Ribi C., Kuntzer T., Michielin O., Peters S., Coukos G., Spertini F. et al., 2019/01. The Lancet. Oncology, 20 (1) pp. e54-e64. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_42DB9145A8A7]
2018
A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.
Horisberger A., La Rosa S., Zurcher J.P., Zimmermann S., Spertini F., Coukos G., Obeid M., 2018/12/27. Journal for immunotherapy of cancer, 6 (1) p. 156. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BD7EE077DFE6]
A severe case of neuro-Sjögren's syndrome induced by pembrolizumab.
Ghosn J., Vicino A., Michielin O., Coukos G., Kuntzer T., Obeid M., 2018/10/22. Journal for immunotherapy of cancer, 6 (1) p. 110. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3E8CC11BAFBA]
Generating the Abscopal Effect by Combining Proapoptotic Peptides With IL-12-Based Immunotherapy.
Martins F., Stalder G., Obeid M., 2018/02. Neoplasia, 20 (2) pp. 193-196. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E40BCA1D786F]
2017
 
Can local radiotherapy and IL-12 synergise to overcome the immunosuppressive tumor microenvironment and allow "in situ tumor vaccination"?
Deplanque G., Shabafrouz K., Obeid M., 2017/07. Cancer immunology, immunotherapy, 66 (7) pp. 833-840. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DF545C7C57EE]
2013
 
Skin-draining lymph node priming is sufficient to induce sterile immunity against pre-erythrocytic malaria.
Obeid M., Franetich J.F., Lorthiois A., Gego A., Grüner A.C., Tefit M., Boucheix C., Snounou G., Mazier D., 2013/02. EMBO molecular medicine, 5 (2) pp. 250-263. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_92D899C6A852]
2009
 
Anticancer activity of targeted proapoptotic peptides and chemotherapy is highly improved by targeted cell surface calreticulin-inducer peptides.
Obeid M., 2009/09. Molecular cancer therapeutics, 8 (9) pp. 2693-2707. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9BA315B57CB9]
2008
 
ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin.
Obeid M., 2008/08/15. Journal of immunology, 181 (4) pp. 2533-2543. Peer-reviewed.
[WoS][Pmid][serval:BIB_B6727AA60C37]
 
Cancer is not just a disease of a tissue: it is a host disease. How to reactivate host defense against tumors using conventional therapies of cancer?
Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Mignot G., Ullrich E., Kroemer G., Zitvogel L., 2008/04. Annales d'endocrinologie, 69 (2) pp. 151-152. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0F38E2F27CCB]
2007
 
Ecto-calreticulin in immunogenic chemotherapy.
Obeid M., Tesniere A., Panaretakis T., Tufi R., Joza N., van Endert P., Ghiringhelli F., Apetoh L., Chaput N., Flament C. et al., 2007/12. Immunological reviews, 220 pp. 22-34. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_73A26D3A014F]
 
Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis
Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, Zitvogel L, Kroemer G, 2007/10. Cell Death and Differentiation, 14 (10) pp. 1848-1850. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_71454B44FDEF]
 
Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference.
Chaput N., De Botton S., Obeid M., Apetoh L., Ghiringhelli F., Panaretakis T., Flament C., Zitvogel L., Kroemer G., 2007/10. Journal of molecular medicine, 85 (10) pp. 1069-1076. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1ABCF83EC0BD]
 
Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic.
Obeid M., Panaretakis T., Tesniere A., Joza N., Tufi R., Apetoh L., Ghiringhelli F., Zitvogel L., Kroemer G., 2007/09/01. Cancer research, 67 (17) pp. 7941-7944. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_86C81A685CC8]
 
Calreticulin exposure dictates the immunogenicity of cancer cell death.
Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., Castedo M., Mignot G., Panaretakis T., Casares N. et al., 2007/01. Nature medicine, 13 (1) pp. 54-61. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BDFD105248D4]
 
Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells.
Apetoh L., Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Piacentini M., Kroemer G., Zitvogel L., 2007. Cancer genomics & proteomics, 4 (2) pp. 65-70. Peer-reviewed.
[Pmid][serval:BIB_78F72692CC21]
 
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P. et al., 2007. Nature Medicine, 13 (9) pp. 1050-1059. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_131A9EB0C182]
2005
 
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.
Casares N., Pequignot M.O., Tesniere A., Ghiringhelli F., Roux S., Chaput N., Schmitt E., Hamai A., Hervas-Stubbs S., Obeid M. et al., 2005/12/19. The Journal of experimental medicine, 202 (12) pp. 1691-1701. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_15F9FF107E5B]
1994
 
Submammary approach for the excision of mammographically localised lesions of the breast.
Winslet M.C., Obeid M.L., 1994/04. The European journal of surgery = Acta chirurgica, 160 (4) pp. 209-211. Peer-reviewed.
[WoS][Pmid][serval:BIB_10EA687F1BF2]
1993
 
On-table pneumoperitoneum in the management of complicated incisional hernias.
Winslet M.C., Kumar V., Obeid M.L., 1993/05. Annals of the Royal College of Surgeons of England, 75 (3) pp. 186-188. Peer-reviewed.
[WoS][Pmid][serval:BIB_C5FAEEB05819]
1989
 
Relation between ventricular function and antiarrhythmic responses to sotalol.
Singh S.N., Chen Y.W., Cohen A., Obeid M., Tracy C., Woosley R.L., Fletcher R.D., 1989/10/15. The American journal of cardiology, 64 (14) pp. 943-945. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3B84115C3EBC]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University